|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Noffsinger A and Waxman I: Preinvasive
neoplasia in the stomach: diagnosis and treatment. Clin
Gastroenterol Hepatol. 9:1018–1023. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Resende C, Ristimäki A and Machado JC:
Genetic and epigenetic alteration in gastric carcinogenesis.
Helicobacter. 1:34–39. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Venkateshwari A, Krishnaveni D, Venugopal
S, Shashikumar P, Vidyasagar A and Jyothy A: Helicobacter
pylori infection in relation to gastric cancer progression.
Indian J Cancer. 48:94–98. 2011. View Article : Google Scholar
|
|
5
|
Loh M, Koh KX, Yeo BH, et al:
Meta-analysis of genetic polymorphisms and gastric cancer risk:
variability in associations according to race. Eur J Cancer.
45:2562–2568. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gao L, Nieters A and Brenner H: Cell
proliferation-related genetic polymorphisms and gastric cancer
risk: systematic review and meta-analysis. Eur J Hum Genet.
17:1658–1667. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tashiro K, Tada H, Heilker R, Shirozu M,
Nakano T and Honjo T: Signal sequence trap: a cloning strategy for
secreted proteins and type I membrane proteins. Science.
261:600–603. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nagasawa T, Kikutani H and Kishimoto T:
Molecular cloning and structure of a pre-B-cell growth-stimulating
factor. Proc Natl Acad Sci USA. 91:2305–2309. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bleul CC, Fuhlbrigge RC, Casasnovas JM,
Aiuti A and Springer TA: A highly efficacious lymphocyte
chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med.
184:1101–1109. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bleul CC, Farzan M, Choe H, et al: The
lymphocyte chemoattractant SDF-1 is a ligand for LELESTR/fusin and
blocks HIV-1 entry. Nature. 382:829–833. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tachibana K, Hirota S, Iizasa H, et al:
The chemokine receptor CXCRCR4 is essential for vascularization of
the gastrointestinal tract. Nature. 393:591–594. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vandercappellen J, Van Damme J and Struyf
S: The role of CXC chemokines and their receptors in cancer. Cancer
Lett. 267:226–244. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kucia M, Reca R, Miekus K, et al:
Trafficking of normal stem cells and metastasis of cancer stem
cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4
axis. Stem Cells. 23:879–894. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zheng K, Li HY, Su XL, Wang XY, Tian T, Li
F and Ren GS: Chemokine receptor CXCR7 regulates the invasion,
angiogenesis and tumor growth of human hepatocellular carcinoma
cells. J Exp Clin Cancer Res. 29:312010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Watanabe MA, de Oliveira Cavassin GG,
Orellana MD, Milanezi CM, Voltarelli JC, Kashima S and Covas DT:
SDF-1 gene polymorphisms and syncytia induction in Brazilian HIV-1
infected individuals. Microb Pathog. 35:31–34. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dean M, Carrington M and O'Brien SJ:
Balanced polymorphism selected by genetic versus infectious human
disease. Annu Rev Genomics Hum Genet. 3:263–292. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Voevodin A, Samilchuk E and Dashti S:
Frequencies of SDF-1 chemokine, CCRCCRCCR-5 and CCRCCRCCR-2
chemokine receptor gene alleles conferring resistance to human
immunodeficiency virus type 1 and AIDS in Kuwaitis. J Med Virol.
58:54–58. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Winkler C, Modi W, Smith MW, et al:
Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene
variant. ALIVE Study, Hemophilia Growth and Development Study
(HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter
Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC).
Science. 279:389–393. 1998.
|
|
19
|
Sei S, O'Neill DP, Stewart SK, et al:
Increased level of stromal cell-derived factor-1 mRNA in peripheral
blood mononuclear cells from children with AIDS-related lymphoma.
Cancer Res. 61:5028–5037. 2001.PubMed/NCBI
|
|
20
|
Ide A, Kawasaki E, Abiru N, et al:
Stromal-cell derived factor-1 chemokine gene variant is associated
with type 1 diabetes age at onset in Japanese population. Hum
Immunol. 64:973–978. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hassan S, Baccarelli A, Salvucci O and
Basik M: Plasma stromal cell-derived factor-1: host derived marker
predictive of distant metastasis in breast cancer. Clin Cancer Res.
14:446–454. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Khademi B, Razmkhah M, Erfani N,
Gharagozloo M and Ghaderi A: SDF-1 and CCR5 genes polymorphism in
patients with head and neck cancer. Pathol Oncol Res. 14:45–50.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hirata H, Hinoda Y, Kikuno N, et al:
CXCL12 G801A polymorphism is a risk factor for sporadic prostate
cancer susceptibility. Clin Cancer Res. 13:5056–5062. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nahon P, Sutton A, Rufat P, et al:
Chemokine system polymorphisms, survival and hepatocellular
carcinoma occurrence in patients with hepatitis C virus-related
cirrhosis. World J Gastroenterol. 14:713–719. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Razmkhah M, Doroudchi M, Ghayumi SM,
Erfani N and Ghaderi A: Stromal cell-derived factor-1 (SDF-1) gene
and susceptibility of Iranian patients with lung cancer. Lung
Cancer. 49:311–315. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Coelho A, Calcada C, Catarino R, Pinto D,
Fonseca G and Medeiros R: CXCLCL12-3′ A polymorphism and lung
cancer metastases protection: new perspectives in immunotherapy?
Cancer Immunol Immunother. 55:639–643. 2006.
|
|
27
|
Razmkhah M, Talei AR, Doroudchi M,
Khalili-Azad T and Ghaderi A: Stromal cell-derived factor-1 (SDF-1)
alleles and susceptibility to breast carcinoma. Cancer Lett.
225:261–266. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dimberg J, Hugander A, Lofgren S and
Wagsater D: Polymorphism and circulating levels of the chemokine
CXCLCL12 in colorectal cancer patients. Int J Mol Med. 19:11–15.
2007.
|
|
29
|
Hidalgo-Pascual M, Galan JJ, Chaves-Conde
M, et al: Analysis of CXCL12 3′UTR G>A polymorphism in
colorectal cancer. Oncol Rep. 18:1583–1587. 2007.
|
|
30
|
Theodoropoulos GE, Panoussopoulos GS,
Michalopoulos NV, et al: Analysis of the stromal cell-derived
factor 1-3′A gene polymorphism in pancreatic cancer. Mol Med
Report. 3:693–698. 2010.
|
|
31
|
Ambrosini G, Adida C and Alteri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Deveraux QL and Reed JC: IAP family
proteins - suppressors of apoptosis. Genes Dev. 13:239–252. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li F, Ambrosini G, Chu EY, et al: Control
of apoptosis and mitotic spindle checkpoint by survivin. Nature.
396:580–584. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Altieri DC: The molecular basis and
potential role of survivin in cancer diagnosis and therapy. Trends
Mol Med. 7:542–547. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liston P, Fong WG and Korneluk RG: The
inhibitors of apoptosis: there is more to life than Bcl2. Oncogene.
22:8568–8580. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Thompson CB: Apoptosis is the pathogenesis
and treatment of disease. Science. 267:1456–1462. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Raff M: Cell suicide for beginners.
Nature. 396:119–122. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tamm I, Wang Y, Sausville E, et al:
IAP-family protein survivin inhibits caspase activity and apoptosis
induced by Fas (CD95), Bax, caspases and anticancer drugs. Cancer
Res. 58:5315–5320. 1998.PubMed/NCBI
|
|
39
|
Asanuma K, Moriai R, Yajima T, et al:
Survivin as a radioresistance factor in pancreatic cancer. Jpn J
Cancer Res. 91:1204–1209. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kawasaki H, Toyoda M, Shinohara H, et al:
Expression of survivin correlates with apoptosis, proliferation and
angiogenesis during human colorectal tumorigenesis. Cancer.
91:2026–2032. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Altieri DC: Survivin, cancer networks and
pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen WC, Liu Q, Fu JX and Kang SY:
Expression of survivin and its significance in colorectal cancer.
World J Gastroenterol. 10:2886–2889. 2004.PubMed/NCBI
|
|
43
|
Falleni M, Pellegrini C, Marchetti A, et
al: Survivin gene expression in early-stage non-small cell lung
cancer. J Pathol. 200:620–626. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fields AC, Cotsonis G, Sexton D,
Santoianni R and Cohen C: Survivin expression in hepatocellular
carcinoma: correlation with proliferation, prognostic parameters
and outcome. Mod Pathol. 17:1378–1385. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu BB and Wang WH: Survivin and
pancreatic cancer. World J Clin Oncol. 2:164–168. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang W, Luo H and Wang A: Expression of
survivin and correlation with PCNA in osteosarcoma. J Surg Oncol.
93:578–584. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Altieri DC, Marchisio PC and Marchisio C:
Survivin apoptosis: an interloper between cell death and cell
proliferation in cancer. Lab Invest. 79:1327–1333. 1999.PubMed/NCBI
|
|
48
|
Xu Y, Fang F, Ludewig G, Jones G and Jones
D: A mutation found in the promoter region of the human survivin
gene is correlated to overexpression of survivin in cancer cells.
DNA Cell Biol. 23:527–537. 2004. View Article : Google Scholar
|
|
49
|
Borbély AA, Murvai M, Szarka K, et al:
Survivin promoter polymorphism and cervical carcinogenesis. J Clin
Pathol. 60:303–306. 2007.
|
|
50
|
Jang JS, Kim KM, Kang KH, et al:
Polymorphisms in the survivin gene and the risk of lung cancer.
Lung Cancer. 60:31–39. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Theodoropoulos GE, Michalopoulos NV,
Panoussopoulos SG, Taka S and Gazouli M: Effects of caspase-9 and
survivin gene polymorphisms in pancreatic cancer risk and tumor
characteristics. Pancreas. 39:976–980. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Yang L, Zhu H, Zhou B, et al: The
association between the survivin C-31G polymorphism and gastric
cancer risk in a Chinese population. Dig Dis Sci. 54:1021–1028.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Cheng ZJ, Hu LH and Huang SJ: Correlation
of -31G/C polymorphisms of survivin promoter to tumorigenesis of
gastric carcinoma. Ai Zheng. 27:258–263. 2008.(In Chinese).
|
|
54
|
Sobin LH and Wittekind C: UICC TNM
Classification of Malignant Tumours. 5th edition. Wiley-Liss; New
York, NY: 1997
|
|
55
|
Juarez J, Bendall L and Bradstock K:
Chemokines and their receptors as therapeutic targets: the role of
the SDF-1/CXCR4 axis. Curr Pharm Res. 10:1245–1259. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Iwasa S, Yanagawa T, Fan J and Katoh R:
Expression of CXCR4 and its ligand SDF-1 in intestinal-type gastric
cancer is associated with lymph node and liver metastasis.
Anticancer Res. 29:4751–4758. 2009.PubMed/NCBI
|
|
57
|
Ishigami S, Natsugoe S, Okumura H, et al:
Clinical implication of CXCL12 in gastric cancer. Ann Surg Oncol.
14:3154–3158. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Woo IS, Hong SH, Byun JH, Kang JH, Jeon HM
and Choi MG: Circulating stromal cell derived factor-1 is
predictive of distant metastasis in gastric carcinoma. Cancer
Invest. 26:256–261. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zhao BC, Wang ZJ, Mao WZ, et al:
CXCR4/SDF-1 axis is involved in lymph node metastasis of gastric
carcinoma. World J Gastroenterol. 17:2389–2396. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Wang YH, Chiou HY, Lin CT, et al:
Association between survivin gene promoter -31 C/G polymorphism and
urothelial carcinoma risk in Taiwanese population. Urology.
73:670–674. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Xu Y, Fang F, Ludewig G, et al: A mutation
found in the promoter region of the human survivin gene is
correlated to overexpression of survivin in cancer cells. DNA Cell
Biol. 23:419–429. 2004. View Article : Google Scholar
|
|
62
|
Xang X, Xiong G, Chen X, et al:
Polymorphisms of survivin promoter are associated with risk of
esophageal squamous cell carcinoma. J Cancer Res Clin Oncol.
135:1341–1349. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Gazouli M, Tzanakis N, Rallis G, et al:
Survivin -31G/C promoter polymorphism and sporadic colorectal
cancer. Int J Colorectal Dis. 24:145–150. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Qin C, Cao Q, Li P, et al: Functional
promoter -31G>C variant in survivin gene is associated with risk
and progression of renal cell cancer in a Chinese population. PLoS
One. 7:e288292012.
|
|
65
|
Yazdani N, Sayahpour FA, Haghpanah V, et
al: Survivin gene polymorphism association with papillary thyroid
carcinoma. Pathol Res Pract. 208:100–103. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Jaiswal PK, Goel A, Mandhani A and Mittal
RD: Functional polymorphisms in promoter survivin gene and its
association with susceptibility to bladder cancer in North Indian
cohort. Mol Biol Rep. 39:5615–5621. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zahedi P, Aminimoghaddam S, Sayahpour FA,
et al: Association of survivin gene polymorphism with endometrial
cancer. Int J Gynecol Cancer. 22:35–37. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Ma F, Zhang H, Zhai Y, et al: Functional
polymorphism -31C/G in the promoter of BIRC5 gene and risk of
nasopharyngeal carcinoma among chinese. PLoS One. 6:e167482011.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Upadhyay R, Khurana R, Kumar S, Ghoshal UC
and Mittal B: Role of survivin gene promoter polymorphism
(-31G>C) in susceptibility and survival of esophageal cancer in
northern India. Ann Surg Oncol. 18:880–887. 2011. View Article : Google Scholar
|
|
70
|
Li Y, Wang J, Jiang F, Lin W and Meng W:
Association of polymorphisms in survivin gene with the risk of
hepatocellular carcinoma in Chinese han population: a case control
study. BMC Med Genet. 13:12012. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Borges BN, Burbano RR and Harada ML:
Survivin -31C/G polymorphism and gastric cancer risk in a Brazilian
population. Clin Exp Med. 11:189–193. 2011. View Article : Google Scholar : PubMed/NCBI
|
